cancer-therapy-and-biomarkers-2016_tracks-abstracts

35 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 66
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
Comparative study of the levels of interleukin-27 and interleukin-17 in pleural fluid of patients
with cause of exudative pleural effusions
Mohammad Reza Hashempour1, Ali Aryannia2, Mahshid Mehrjerdian 3, Mojtaba Kiani4 and Gholam Reza Roshandel5
15Azar Hospital-Golestan University of Medical Sciences, Iran
2Taleghani Hospital-Golestan University of Medical Sciences, Iran
3Sayyad Shirazi Hospital-Golestan University of Medical Sciences, Iran
Pleural effusion is one of signs and complications resulting from malignant diseases such aslung and breast cancer, and also
tuberculosis and infective lung disease. Diagnostic evaluationfor patients with pleural effusion include history, physical
exam, chest x-ray and if necessarythoracocentesis and cytologic analysis of pleural fluid. According to cytologic evaluation
ofpleural fluid, pleural effusion divide in two group: exudative and transudative, that exudativepleural effusion require more
diagnostic evaluations. By cytologic analysis of pleural fluid wecan use of tumor markers and other biomarkers to better di-
agnose malignant pleural effusion. Inthe previous studies by using immunochemical approach, interleukin-17 and also CEA
expressin more amounts in malignant pleural effusion than in benign pleural effusion, in contrast tointerleukin-27. In this
study we examined the concentration of Interleukin-27 & 17 in PleuralFluid with Causes of Exudative Pleural Effusion in the
Patients Referred to educational Hospitalof Gorgan of Iran in 2015-16. This is a descriptive-analytical and case-control study
and 130patient with exudative pleural effusion were enrolled in the study after an informed consent.Samples collected from
the patients divided in two main group including 88 patients withmalignant pleural effusion and 42 patients with benign
pleural effusion. In next step by using ofthe same previous pleural fluid samples, the concentration of Interleukin-27 & 17 was
measuredwith ELISA by an specific Kit. After entering to computer through SPSS-18 statistical software,description of data
was done into frequency and percentage. Interleukin-27 concentration was(203.05±76.03) in patients with malignant caus-
es and (344.15±236.42) in benign causesspecially tuberculosis. Interleukin-17 concentration was (69.73±64.58) in patients
with malignantcauses and (55.32±43.60) in benign causes.The results showed that these difference werestatistically significant
(p=0.000 for IL27) and (p=0.02 for IL17). In other word interleukin-27level, is higher in the benign pleural effusions and
interleukin-17 level, is higher in the malignantpleural effusions. According to higher levels of interleukin-27 in benign pleural
effusions andhigher level of interleukin-17 in malignant pleural effusions, maybe we can achieve importantresults in differen-
tiating between malignant and non-malignant pleural exudate, without the needfor invasive procedures, by putting together
the clinical symptoms, the interleukins concentrationin pleural fluid and pleural fluid cytology results.
Biography
Mohammad Reza Hashempour has completed his Doctorate from Army University of Medical Sciences and Postdoctoral studies in Surgery from Golestan
University School of Medicine. He has published papers in reputed journals.
Mohammad Reza Hashempour et al., Oncol Cancer Case Rep 2016,2:3(Suppl)